+

WO2002017970A3 - Metal radionuclide labelled cd-30 antibodies and uses thereof - Google Patents

Metal radionuclide labelled cd-30 antibodies and uses thereof Download PDF

Info

Publication number
WO2002017970A3
WO2002017970A3 PCT/US2001/026335 US0126335W WO0217970A3 WO 2002017970 A3 WO2002017970 A3 WO 2002017970A3 US 0126335 W US0126335 W US 0126335W WO 0217970 A3 WO0217970 A3 WO 0217970A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
immunoconjugates
metal radionuclide
radionuclide labelled
labelled
Prior art date
Application number
PCT/US2001/026335
Other languages
French (fr)
Other versions
WO2002017970A2 (en
Inventor
Fook Thean Lee
Andrew Scott
Christoph Renner
Michael Pereundschuh
Original Assignee
Ludwig Inst Cancer Res
Fook Thean Lee
Andrew Scott
Christoph Renner
Michael Pereundschuh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Fook Thean Lee, Andrew Scott, Christoph Renner, Michael Pereundschuh filed Critical Ludwig Inst Cancer Res
Priority to AU2001286663A priority Critical patent/AU2001286663A1/en
Publication of WO2002017970A2 publication Critical patent/WO2002017970A2/en
Publication of WO2002017970A3 publication Critical patent/WO2002017970A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to metallic radionuclide containing immunoconjugates. The immunoconjugates bind specifically to the CD30 molecule. Both diagnostic and therapeutic uses of the immunoconjugates are described. The preferred immunoconjugates are monoclonal antibodies to which ?111In or 90¿Y is bound via a chelator.
PCT/US2001/026335 2000-08-28 2001-08-23 Metal radionuclide labelled cd-30 antibodies and uses thereof WO2002017970A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001286663A AU2001286663A1 (en) 2000-08-28 2001-08-23 Metal radionuclide labelled cd-30 antibodies and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64948900A 2000-08-28 2000-08-28
US09/649,489 2000-08-28

Publications (2)

Publication Number Publication Date
WO2002017970A2 WO2002017970A2 (en) 2002-03-07
WO2002017970A3 true WO2002017970A3 (en) 2003-01-09

Family

ID=24605007

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/026335 WO2002017970A2 (en) 2000-08-28 2001-08-23 Metal radionuclide labelled cd-30 antibodies and uses thereof

Country Status (2)

Country Link
AU (1) AU2001286663A1 (en)
WO (1) WO2002017970A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007437A2 (en) * 1989-11-20 1991-05-30 Parker, David, L. Improved cd-30 antibodies and fragments thereof
WO1991007941A2 (en) * 1989-11-20 1991-06-13 Imperial Cancer Research Technology Limited Methods and compositions for the treatment of hodgkin's disease
WO1994004189A1 (en) * 1992-08-25 1994-03-03 Medac Gesellschaft Fur Klinische Spezialpräparate Mbh Antibody/radioisotope conjugate for tumor diagnosis and/or therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007437A2 (en) * 1989-11-20 1991-05-30 Parker, David, L. Improved cd-30 antibodies and fragments thereof
WO1991007941A2 (en) * 1989-11-20 1991-06-13 Imperial Cancer Research Technology Limited Methods and compositions for the treatment of hodgkin's disease
WO1994004189A1 (en) * 1992-08-25 1994-03-03 Medac Gesellschaft Fur Klinische Spezialpräparate Mbh Antibody/radioisotope conjugate for tumor diagnosis and/or therapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HEEGER S ET AL: "Alpha-radioimmunotherapy of B-cell non Hodgkin's lymphoma: Preclinical evaluation of 213Bi-labeled CD19- and CD20-CHX-A''-DTPA conjugates.", ONKOLOGIE, vol. 23, no. Sonderheft 7, October 2000 (2000-10-01), Annual Meeting of the German and Austrian Society for Hematology and Oncology;Graz, Austria; October 21-25, 2000, pages 47, XP008008867, ISSN: 0378-584X *
HORN-LOHRENS O ET AL: "Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4).", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER. UNITED STATES 8 FEB 1995, vol. 60, no. 4, 8 February 1995 (1995-02-08), pages 539 - 544, XP008008865, ISSN: 0020-7136 *
NIKULA TUOMO K ET AL: "A Rapid, Single Vessel Method for Preparation of Clinical Grade Ligand Conjugated Monoclonal Antibodies.", NUCLEAR MEDICINE AND BIOLOGY, vol. 22, no. 3, 1995, pages 387 - 390, XP004051802, ISSN: 0969-8051 *
RENNER, CHRISTOPH ET AL: "Targeting properties of an anti-CD16/anti- CD30 bispecific antibody in an in vivo system", CANCER IMMUNOLOGY IMMUNOTHERAPY (2001), 50(2), 102-108, XP002215906 *

Also Published As

Publication number Publication date
WO2002017970A2 (en) 2002-03-07
AU2001286663A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
IL158643A (en) Anti-hmg monoclonal antibodies and compositions containing the same
EP1406656A4 (en) METHODS OF ADMINISTERING ANTI-TNF$g(a) ANTIBODIES
EE05309B1 (en) β-Am Looid Peptide "Humanized Antibodies, Method for Their Preparation, Their Use, and Pharmaceutical Composition
EP3569610A3 (en) Molecules with extended half lives, compositions and uses thereof
ZA200206266B (en) Antibodies that bind human interleukin-18 and methods of making and using.
PL354112A1 (en) Application of anti-ctla-4 antibodies
WO2003040288A3 (en) Isotopically coded affinity markers 3
IL207060A0 (en) Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
EP1516185A4 (en) PRESENTATION OF MONOCLONAL ANTIBODIES AND TREATMENT OF TUMORS EXPRESSING MET AND BINDING THE HEPATOCYTIC GROWTH FACTOR
IL132304A (en) Use of an antibody which binds to osteoprotegerin to make a pharmaceutical composition
DE60142342D1 (en) ANTIBODIES TO DUAL INGREDIENTS, COMPOSITIONS, PROCESSES AND USES
HK1081647A1 (en) N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
HK1092375A1 (en) Use of radiolabelled antibody l19 against fibronectin ed-b in the preparation of a medicament for targeting of tumor vasculature
ZA200200011B (en) Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof.
BR9913084A (en) Antithrombotic agent and monoclonal antibody with humanized anti-willebrand factor
AU2001290315A1 (en) Anti-cd14 monoclonal antibody having effect of inhibiting cd14/tlr binding
AU9373501A (en) Use of antibodies against specific mhc-peptide complexes
JP2004510683A5 (en)
WO2005053752A3 (en) Novel imaging agents comprising caspase-3 inhibitors
WO1998014220A3 (en) Technetium-99m labeled chelator incorporated cyclic peptides
WO2001051644A3 (en) ANTI-CD3 SINGLE-CHAIN ANTIBODIES HAVING HUMAN Cν3 AND Cν4 DOMAINS
IL175646A0 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
WO2003026700A3 (en) Compositions for transporting antibodies through the blood brain barrier and their use for diagnosing or treating central nervous system diseases
WO2002017970A3 (en) Metal radionuclide labelled cd-30 antibodies and uses thereof
EP1434799A4 (en) DNA MOLECULES AND RECOMBINANT DNA MOLECULES FOR THE PREPARATION OF HUMANIZED MONOCLONAL ANTIBODIES TO S.MUTANS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载